Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

156 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Epstein-Barr virus-specific intrathecal oligoclonal IgG production in relapsing-remitting multiple sclerosis is limited to a subset of patients and is composed of low-affinity antibodies.
Castellazzi M, Contini C, Tamborino C, Fasolo F, Roversi G, Seraceni S, Rizzo R, Baldi E, Tola MR, Bellini T, Granieri E, Fainardi E. Castellazzi M, et al. J Neuroinflammation. 2014 Nov 13;11:188. doi: 10.1186/s12974-014-0188-1. J Neuroinflammation. 2014. PMID: 25391491 Free PMC article.
Presence of detectable levels of soluble HLA-G molecules in CSF of relapsing-remitting multiple sclerosis: relationship with CSF soluble HLA-I and IL-10 concentrations and MRI findings.
Fainardi E, Rizzo R, Melchiorri L, Vaghi L, Castellazzi M, Marzola A, Govoni V, Paolino E, Tola MR, Granieri E, Baricordi OR. Fainardi E, et al. Among authors: castellazzi m. J Neuroimmunol. 2003 Sep;142(1-2):149-58. doi: 10.1016/s0165-5728(03)00266-2. J Neuroimmunol. 2003. PMID: 14512174
Beneficial effect of interferon-beta 1b treatment in patients with relapsing-remitting multiple sclerosis is associated with an increase in serum levels of soluble HLA-I molecules during the first 3 months of therapy.
Fainardi E, Rizzo R, Melchiorri L, Castellazzi M, Govoni V, Caniatti L, Paolino E, Tola MR, Granieri E, Baricordi OR. Fainardi E, et al. Among authors: castellazzi m. J Neuroimmunol. 2004 Mar;148(1-2):206-11. doi: 10.1016/j.jneuroim.2003.12.002. J Neuroimmunol. 2004. PMID: 14975603 Clinical Trial.
156 results